Shop by goal

Popular compounds

GHK-Cu Copper Peptide

Retatrutide

Research resources

Cerebrolysin Research Peptide Complex

Q: What is Cerebrolysin and what is it made of?

Cerebrolysin (FPF-1070) is a standardised low-molecular-weight fraction of polypeptides produced by enzymatic hydrolysis of purified porcine brain proteins - roughly 85% free amino acids plus a smaller bioactive peptide fraction, standardised to 215.2 mg/mL. The peptide fraction is what carries neurotrophic activity mimicking endogenous factors like BDNF, NGF and GDNF. It is supplied for laboratory research only.

Q: Is Cerebrolysin a single peptide or a mixture?

It is a standardised mixture - a defined enzymatic hydrolysate of porcine brain tissue dominated by free amino acids with a low-molecular-weight (<10 kDa) bioactive peptide fraction. The ratios are manufactured to pharmaceutical specifications, so batch-to-batch variability is controlled, even though the product is not a single molecule.

Q: Is Cerebrolysin FDA-approved, and where is it approved?

Cerebrolysin is not FDA-approved in the United States and is sold here strictly as a research compound, not for human use. It is approved and marketed as a medicine in a number of other countries (for example Austria, Germany, China, Russia and South Korea) for indications including stroke, traumatic brain injury and dementia. Legal status varies by jurisdiction.

Q: What does the stroke and dementia research actually show?

The evidence is genuinely mixed, which is worth stating plainly. A 2018 meta-analysis of nine RCTs (N=1,879) reported early reduction of neurological deficit versus placebo, while the more conservative 2023 Cochrane review found moderate-certainty evidence of probably little-to-no difference in all-cause death in acute ischaemic stroke. Alzheimer's trials report cognitive improvements, including combination studies with donepezil. These are research findings, not a treatment claim.

Q: Why use Cerebrolysin instead of individual growth factors like BDNF?

Small recombinant growth factors like BDNF are difficult to deliver to the brain because of their size and blood-brain-barrier exclusion, and they have very short half-lives in circulation. Cerebrolysin's peptide fraction is small enough to act centrally and collectively mimics the activity of several neurotrophic factors, which is why it is used as a tool compound for neurotrophic-signalling research.

Q: What does published safety reporting say?

Clinical studies of the licensed preparation report generally mild adverse events (for example transient dizziness or agitation) and list contraindications in status epilepticus and severe renal impairment. Those are findings about that medicine in its clinical studies. This page publishes no amount, route or schedule, and the material supplied here is for laboratory research only.

Q: How should Cerebrolysin be stored?

Cerebrolysin is supplied as an aqueous solution rather than a lyophilised powder. Store at 2-8 °C in a refrigerator - do not freeze, as freezing can cause precipitation of the peptide fraction. Protect from light. Once opened, use within the product's specified stability window.

Q: Where can I buy Cerebrolysin?

Right here - Cerebrolysin is supplied directly by New-U Research Compounds on this page as lyophilised research-grade material with a Standardized pharmaceutical preparation purity specification, and shipped direct from source worldwide in discreet, tracked packaging.

Q: How much does Cerebrolysin cost?

Cerebrolysin pricing is shown live on this page, per pack size - sealed 10-vial research packs, or single vials where listed (an order needs at least 3 single vials in total, or any 10-vial pack). Larger vial strengths lower the per-mg cost, and shipping is free on orders over $350.

Q: How do I buy Cerebrolysin?

Add the Cerebrolysin pack size you need to your cart and check out: enter your shipping details, then choose your payment method - cryptocurrency or card - on the next step.

aka Cerebrolysin, FPF-1070, Porcine Brain-Derived Peptide Preparation, Brain-Derived Neurotrophic Peptide Complex, CERE, Renacenz

Cerebrolysin (FPF-1070) is a standardised enzymatic hydrolysate of porcine brain tissue: a peptide preparation of free amino acids and low-molecular-weight neuropeptides under 10 kDa. Its literature studies neurotrophic-like signalling through PI3K/Akt and MAPK/ERK pathways, and the licensed medicinal preparation has stroke and dementia trials ranging from a positive meta-analysis to a more cautious Cochrane review. New-U supplies Cerebrolysin as an aqueous peptide concentrate in vials. Findings from the licensed preparation must not be transferred to this research material.

Product features

Purity specification Standardized pharmaceutical preparation Catalogue specification for this material.

Vial strengths 30 mg · 60 mg 2 strengths, all in stock. Pick one in the selector.

Formats Single vial · 10-vial pack Price per vial and pack total update with your selection.

This strength is out of stock. Pick another strength, or check back soon — restocks are frequent.

Available in 30 mg, 60 mg vials

Dispatched within 24 hours of confirmed payment on business days, shipped worldwide

Cerebrolysin Research Peptide Complex

Compare pack sizes

Tap a pack to select it

Buy the 10-pack - save 61%/mg. Single vials welcome — checkout needs 3+ vials or any 10-vial pack - build a custom vial pack

Lab-direct quality — full packs or single-vial samples

Every batch ships straight from the lab that synthesises it — sealed, tamper-evident, and supplied to a Standardized pharmaceutical preparation purity specification . Buying direct means you pay the lab-direct rate on every vial, with nothing stacked on top.

Order a sealed 10-vial research pack , or mix single vials across compounds and strengths — an order needs at least 3 single vials in total, or any 10-vial pack. Same source, same purity specification — scaled to whatever your research needs.

What It's Researched For

In plain terms, Cerebrolysin is studied as a brain-protection and recovery peptide, mostly after stroke or injury. Here is what that looks like across the research.

Neuroprotection & recovery

The licensed preparation has been investigated in clinical studies after stroke and head injury; the published results are mixed and concern that medicine, not this research material.

Memory & dementia

Clinical studies of the licensed preparation have examined cognitive endpoints in dementia; this page reports them as external findings only.

Brain growth-signal support

Research looks at how its small peptides act like the brain's own growth and survival signals to support nerve cells.

Neuronal culture models

Used in cell-culture and animal models of neuronal survival, differentiation and synaptic plasticity.

Scientific Overview

In short: Cerebrolysin is the name of a standardised porcine brain-derived peptide preparation that is licensed as a medicine in several countries outside the US - a mixture of low molecular weight neuropeptides that functionally mimic BDNF, NGF, GDNF, and CNTF signalling.

Key research facts

Low-MW peptides (<10 kDa) cross the blood-brain barrier to deliver neurotrophic factor-like activity directly to CNS tissue

Activates PI3K/Akt and MAPK/ERK pathways promoting neuronal survival, differentiation, and synaptic plasticity

Reduces APP phosphorylation and Aβ peptide production via GSK3β and CDK5 modulation

Stimulates endogenous upregulation of BDNF, GDNF, and NGF in addition to exogenous peptide supply

Anti-excitotoxic, anti-apoptotic, and antioxidant neuroprotective effects demonstrated in ischemia models

These points summarise lab themes, not human outcomes.

Cerebrolysin is unusual among the peptides on this site: it is not a single defined molecule but a standardised enzymatic hydrolysate of porcine brain tissue. The preparation contains 80% free amino acids and 20% low-molecular-weight neuropeptides (under 10 kDa), and those small peptides carry neurotrophic activity that mimics the major brain growth factors.

The licensed medicinal preparation has a mixed clinical literature. A 2018 meta-analysis of nine randomised controlled trials (1,879 stroke patients) reported early NIHSS benefit versus placebo, while a 2023 Cochrane review found probably little-to-no difference in all-cause death in acute ischaemic stroke. Those are findings about that medicine in its own studies, not properties of the research material supplied here.

Cerebrolysin is supplied here as a standardised pharmaceutical preparation (215.2 mg/mL peptide concentrate in aqueous solution) for in-vitro and preclinical research.

Cerebrolysin (FPF-1070) is a standardized enzymatic hydrolysate of porcine brain tissue comprising 80% free amino acids and 20% biologically active low-molecular-weight neuropeptides (<10 kDa) that functionally mimic BDNF, GDNF, NGF, and CNTF neurotrophic signaling. The peptide fraction activates the PI3K/Akt and MAPK/ERK survival pathways, promoting neuronal proliferation, synaptogenesis, and anti-apoptotic signaling while reducing GSK3β- and CDK5-mediated phosphorylation of amyloid precursor protein (Windisch, Journal of Neural Transmission, 2006). In clinical studies of the licensed medicinal preparation, a meta-analysis of nine RCTs reported early NIHSS benefit versus placebo (MW 0.60, P < 0.0001, N = 1,879; Bornstein et al., 2018), and a 2023 Cochrane review was more cautious; these findings do not transfer to the research material supplied here.

At a glance

Mechanism and receptors Cerebrolysin delivers a mixture of small neurotrophic peptides that activate survival pathways, reduce amyloid processing, and stimulate endogenous neurotrophin production in brain tissue.

Clinical research Ziganshina et al. 2023 (Cochrane Database) - more conservative review finding moderate-certainty evidence of probably little-to-no difference in all-cause death in acute ischaemic stroke; Alzheimer's disease trials of the licensed preparation reporting cognitive endpoints, including combination work alongside donepezil.

Molecular characteristics Molecular weight <10,000 Da (peptide fraction); complex mixture.

Evidence maturity Mixed (human + animal) — Cerebrolysin has a genuinely mixed human evidence base - a positive multi-trial stroke meta-analysis alongside a more cautious Cochrane review, plus dementia trial data. It is an approved medicine in 45+ countries but is NOT FDA-approved; the research-grade preparation supplied here is unapproved laboratory material in the US.

Research limitations Published clinical findings describe the study materials and protocols used by investigators; they do not establish the effects or safety of this research material.

Mechanism of Action

Cerebrolysin delivers a mixture of small neurotrophic peptides that activate survival pathways, reduce amyloid processing, and stimulate endogenous neurotrophin production in brain tissue.

Pathway Effect Why it matters PI3K / Akt Activates neuronal survival and anti-apoptotic signalling Protects neurons in ischemia and injury models MAPK / ERK Drives neuronal differentiation and synaptic plasticity Supports functional recovery after stroke or TBI GSK3β / CDK5 Reduces APP phosphorylation and Aβ production Dampens Alzheimer's-related amyloid processing Endogenous neurotrophins Upregulates BDNF, GDNF, NGF expression Amplifies the brain's own trophic support beyond exogenous peptide supply BBB permeability Small peptides (<10 kDa) cross the blood-brain barrier Delivers trophic activity directly to CNS tissue after peripheral administration

Deeper dive for scientific readers

Cerebrolysin is a low-molecular-weight fraction of polypeptides from porcine brain - roughly 85% free amino acids plus a peptide-nitrogen fraction - standardised to 215.2 mg/mL. Bornstein et al. (Neurological Sciences, 2018) published a meta-analysis of nine stroke RCTs (N = 1,879) reporting superiority over placebo for early reduction of neurological deficit (Mann-Whitney effect size 0.60, P < 0.0001; number-needed-to-treat 7.7) with safety comparable to placebo. The 2023 Cochrane review of Cerebrolysin in acute ischaemic stroke (Ziganshina et al.) is more cautious, concluding moderate-certainty evidence of probably little-to-no difference in all-cause death. Alzheimer's trials have reported cognitive improvements on standard scales, including head-to-head and combination work alongside donepezil.

Common Questions People Are Asking

What is Cerebrolysin and what is it made of?

Cerebrolysin (FPF-1070) is a standardised low-molecular-weight fraction of polypeptides produced by enzymatic hydrolysis of purified porcine brain proteins - roughly 85% free amino acids plus a smaller bioactive peptide fraction, standardised to 215.2 mg/mL. The peptide fraction is what carries neurotrophic activity mimicking endogenous factors like BDNF, NGF and GDNF. It is supplied for laboratory research only.

Is Cerebrolysin a single peptide or a mixture?

It is a standardised mixture - a defined enzymatic hydrolysate of porcine brain tissue dominated by free amino acids with a low-molecular-weight (<10 kDa) bioactive peptide fraction. The ratios are manufactured to pharmaceutical specifications, so batch-to-batch variability is controlled, even though the product is not a single molecule.

Is Cerebrolysin FDA-approved, and where is it approved?

Cerebrolysin is not FDA-approved in the United States and is sold here strictly as a research compound, not for human use. It is approved and marketed as a medicine in a number of other countries (for example Austria, Germany, China, Russia and South Korea) for indications including stroke, traumatic brain injury and dementia. Legal status varies by jurisdiction.

What does the stroke and dementia research actually show?

The evidence is genuinely mixed, which is worth stating plainly. A 2018 meta-analysis of nine RCTs (N=1,879) reported early reduction of neurological deficit versus placebo, while the more conservative 2023 Cochrane review found moderate-certainty evidence of probably little-to-no difference in all-cause death in acute ischaemic stroke. Alzheimer's trials report cognitive improvements, including combination studies with donepezil. These are research findings, not a treatment claim.

Why use Cerebrolysin instead of individual growth factors like BDNF?

Small recombinant growth factors like BDNF are difficult to deliver to the brain because of their size and blood-brain-barrier exclusion, and they have very short half-lives in circulation. Cerebrolysin's peptide fraction is small enough to act centrally and collectively mimics the activity of several neurotrophic factors, which is why it is used as a tool compound for neurotrophic-signalling research.

What does published safety reporting say?

Clinical studies of the licensed preparation report generally mild adverse events (for example transient dizziness or agitation) and list contraindications in status epilepticus and severe renal impairment. Those are findings about that medicine in its clinical studies. This page publishes no amount, route or schedule, and the material supplied here is for laboratory research only.

How should Cerebrolysin be stored?

Cerebrolysin is supplied as an aqueous solution rather than a lyophilised powder. Store at 2-8 °C in a refrigerator - do not freeze, as freezing can cause precipitation of the peptide fraction. Protect from light. Once opened, use within the product's specified stability window.

Where can I buy Cerebrolysin?

Right here - Cerebrolysin is supplied directly by New-U Research Compounds on this page as lyophilised research-grade material with a Standardized pharmaceutical preparation purity specification, and shipped direct from source worldwide in discreet, tracked packaging.

How much does Cerebrolysin cost?

Cerebrolysin pricing is shown live on this page, per pack size - sealed 10-vial research packs, or single vials where listed (an order needs at least 3 single vials in total, or any 10-vial pack). Larger vial strengths lower the per-mg cost, and shipping is free on orders over $350.

How do I buy Cerebrolysin?

Add the Cerebrolysin pack size you need to your cart and check out: enter your shipping details, then choose your payment method - cryptocurrency or card - on the next step.

What payment methods can I use to buy Cerebrolysin?

At checkout you can pay by card or crypto. New-U supports BTC and selected stablecoin and network-asset payments across Ethereum, Solana, TRON, Polygon, Base, BNB Chain and Linea. You choose your method after confirming your order.

How fast is shipping, and do you ship worldwide?

Yes - we ship worldwide in discreet, unmarked, tracked packaging; lyophilised peptides are stable through the tracked transit window. Delivery typically takes 6–14 business days, and shipping is free on orders over $350.

Is it legal to buy Cerebrolysin?

In the United States, Cerebrolysin is sold strictly for laboratory and research purposes only. It is not approved by the FDA for human consumption and is not sold for that purpose. Regulatory status varies by jurisdiction - buyers are responsible for compliance in their own region.

Research use only - all claims made on this site are for testing and research use only.

Pharmacokinetics

Stability 2–8 °C. Do not freeze. Protect from light. Notes Laboratory research material. No amount, route, schedule or administration guidance is published or recommended on this page.

Evidence Tier

Overall: Mixed (human + animal)

Cerebrolysin has a genuinely mixed human evidence base - a positive multi-trial stroke meta-analysis alongside a more cautious Cochrane review, plus dementia trial data. It is an approved medicine in 45+ countries but is NOT FDA-approved; the research-grade preparation supplied here is unapproved laboratory material in the US.

Tier 1 · Human clinical

Bornstein et al. 2018 (Neurological Sciences) - meta-analysis of nine stroke RCTs (N=1,879) reporting early neurological-deficit benefit over placebo (P < 0.0001)

Ziganshina et al. 2023 (Cochrane Database) - more conservative review finding moderate-certainty evidence of probably little-to-no difference in all-cause death in acute ischaemic stroke

Alzheimer's disease trials of the licensed preparation reporting cognitive endpoints, including combination work alongside donepezil

Approved and marketed as a medicine in 45+ countries (e.g. Austria, Germany, China, Russia, South Korea) for stroke, TBI and dementia

Certificates, databases & peer-reviewed sources

Last reviewed: 16 June 2026 · New-U Research Compounds

Bornstein NM, et al. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurological Sciences. · 2018 · PMID: 29248999 · DOI: 10.1007/s10072-017-3214-0

Ziganshina LE, et al. Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews. · 2023 · PMID: 37818733 · DOI: 10.1002/14651858.CD007026.pub7

PubMed: peer-reviewed literature on Cerebrolysin

ClinicalTrials.gov: registered studies on Cerebrolysin

Cerebrolysin: Wikipedia

WebMD: consumer health reference

BBC News: Health

CNN Health: “Peptides: what to know about the wellness trend”

Sky News: “Can peptides make America healthy again?”

Sky News: “Inside the exploding US peptides craze” (video)

Sky News Australia: “Black market peptide trade explodes as influencers fuel uptick in use”

Sky News Australia: “Backyard peptide boom sparks alarm” (video)

Sky News Australia: “Oprah reveals struggle with shame of weight-loss drugs”

Key Characteristics

Standardised porcine brain-derived peptide preparation

80% free amino acids + 20% low-MW neuropeptides (<10 kDa)

Mimics BDNF, NGF, GDNF, and CNTF neurotrophic signalling

Licensed as a medicine outside the US; supplied here only as laboratory research material

Mixed clinical literature (2018 meta-analysis; 2023 Cochrane review)

Supplied as 215.2 mg/mL aqueous concentrate

Pharmaceutical-grade standardised preparation

Specifications

Composition Porcine brain enzymatic hydrolysate (80% free amino acids + 20% peptides) Peptide fraction MW <10,000 Da Concentration 215.2 mg/mL Purity Standardised pharmaceutical preparation Form Aqueous solution (ready to use) Storage 2-8 °C. Do not freeze. Protect from light.

About Cerebrolysin: Porcine Brain-Derived Neuropeptide Complex Research Guide

Cerebrolysin occupies an unusual middle ground in peptide research. It is not a single defined compound the way most research peptides are, and it is also not a crude extract - it is a standardised enzymatic hydrolysate of porcine brain tissue (FPF-1070) that has been manufactured to pharmaceutical specifications since the 1970s. The preparation is a low-molecular-weight fraction comprising roughly 85% free amino acids plus a peptide fraction (standardised to 215.2 mg/mL), and that small-peptide fraction carries neurotrophic activity that mimics endogenous factors such as BDNF and NGF.

The clinical evidence base is comparatively rich for a mixture product, and it is genuinely mixed - which is the honest research picture. The stroke meta-analysis (Bornstein et al., Neurological Sciences, 2018) covers 1,879 patients across nine RCTs and reports early neurological-deficit benefit over placebo, while the more conservative 2023 Cochrane review (Ziganshina et al.) found moderate-certainty evidence of probably little-to-no difference in all-cause death in acute ischaemic stroke. Alzheimer's datasets include head-to-head and combination work alongside donepezil. That spread of comparative data makes Cerebrolysin a useful reference compound for studying peptide-based neurotrophic interventions.

New-U Research Compounds supplies Cerebrolysin as a pharmaceutical-grade aqueous concentrate (215.2 mg/mL) strictly for in-vitro and laboratory research use. Cerebrolysin is not FDA-approved in the United States, though it is approved and marketed in a number of other countries. Note the clinical contraindications reported in status epilepticus and severe renal impairment. Nothing on this page is medical advice or a dose recommendation, and Cerebrolysin should not replace any prescribed treatment.

Cerebrolysin - Wikipedia

Brain-derived neurotrophic factor - Wikipedia

Nerve growth factor - Wikipedia

Stroke - Wikipedia

Bornstein et al. 2018 - Cerebrolysin early post-stroke recovery meta-analysis (PubMed)

Ziganshina et al. 2023 - Cerebrolysin for acute ischaemic stroke, Cochrane review (PubMed)

Customer Reviews

Would use again

Everything went through as it should. Nothing flashy, just an easy order and clear information.

- George M***** · 26 October 2026

Quick to find

Didn't have to search around for ages. Cerebrolysin was right where I'd expect and ordering was easy.

- Heath H***** · 22 October 2026

More in Cognitive / Neuro

Cognitive / Neuro Semax Semax is a synthetic ACTH(4-10) heptapeptide nootropic that upregulates BDNF/TrkB signaling and modulates dopaminergic and serotonergic neurotransmission. Semax →

Cognitive / Neuro Selank Selank is a synthetic tuftsin-derived heptapeptide anxiolytic that allosterically modulates GABAA receptors and upregulates hippocampal BDNF expression. Selank →

Cognitive / Neuro DSIP DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide first isolated from rabbit cerebral venous blood, studied for its association with delta-wave sleep architecture and hypothalamic-pituitary-adrenal axis modulation. DSIP →

Cognitive / Neuro Adamax Adamax is a synthetic Semax-family research peptide - an N-acetylated ACTH(4-10) analogue carrying a C-terminal adamantane modification intended to increase metabolic stability and lipophilicity relative to unmodified Semax. Adamax →

Cognitive / Neuro PE 22-28 PE 22-28 is a seven-residue peptide derived from spadin (PE 12-28), the sortilin-propeptide fragment studied as a TREK-1 (K2P) channel blocker in rodent models. PE 22-28 →

Cerebrolysin vs related Cognitive / Neuro compounds

Compound Price Purity spec COA Cerebrolysin from $117 Standardized pharmaceutical preparation On request Semax from $93 >99% HPLC 2 published batches Selank from $106 >99% HPLC On request

Descriptive catalog comparison for research sourcing decisions - not dosing guidance.

More on Cerebrolysin

Cognitive Research research compounds

Cerebrolysin research guide

Cerebrolysin pricing and packs

Research this compound

Research guide Cerebrolysin research guide Cerebrolysin delivers a mixture of small neurotrophic peptides that activate survival pathways, reduce amyloid processing, and stimulate… Read the guide →

Part of the Cognitive & longevity research research area — explore related compounds, guides and sources.

From our community

What people say on Facebook

Facebook account deactivated

PRECISION. PURITY. PERFORMANCE.

Research peptides. Third-party Certificates of Analysis (Janoshik Analytical & Freedom Diagnostics) are published on the website. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research